| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for Ariad Pharmaceuticals Inc. > News item |
Ariad says finding ex-U.S. partner for AP23573 is top priority
By Jennifer Lanning Drey
Portland, Ore., Nov. 13 - Ariad Pharmaceuticals, Inc.'s top business priority is finding a partner outside of the United States for its lead product candidate, AP23573, or Ariad 573, chief executive officer Dr. Harvey J. Berger said at the JPMorgan Small/Mid Cap Conference in Boston on Monday.
"At the heart of our path forward is our need to leverage the extensive corporate experience that we have with respect to strategic partnerships moving toward profitability," Berger said.
The company expects to announce an ex-U.S. partnership deal for Ariad 573 late this year or early in 2007, he said.
Also within that timeframe, Ariad plans to launch the phase 3 registration trail for Ariad 573 in advanced sarcomas, which the company considers a gateway indication into oncology, Berger said.
Berger also stressed during Monday's presentation that the drug is not just for sarcomas.
"We see opportunity to commercialize [Ariad] 573 across a wide range of cancer indications," he said.
The company will announce guidance on additional indications for Ariad 573 once it has a partnership deal in place, he said.
Ariad's internal objective is to be ready to launch Ariad 573 for sarcomas by the end of 2008; however, Berger said that if approved, the drug will likely be launched early in 2009.
Berger also said that Ariad will announce its next oncology development candidate at the American Society of Hematology 48th Annual Meeting, scheduled for Dec. 9-12 in Orlando, Fla.
Located in Cambridge, Mass., Ariad develops medicines to treat cancer by regulating cell signaling with small molecules.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.